Navigation Links
LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies
Date:2/25/2008

TORRANCE Combined hormone therapy appears to increase the risk that women will have abnormal mammograms and breast biopsies, and it may decrease the effectiveness of both methods for detecting breast cancer, according to a report in the Feb. 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Rowan T. Chlebowski, M.D., Ph.D., a lead investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), was the lead author of the report. He and his colleagues studied 16,608 post-menopausal women who participated in the Womens Health Initiative (WHI) clinical trial, a 15-year study that began in 1993.

The research team examined the effect of combined hormone therapy on breast cancer detection over five years and found it resulted in more than one in 10 women having otherwise avoidable mammogram abnormalities and one in 25 women having breast biopsies. Combined hormone therapy also compromised the diagnostic performance of mammograms and breast biopsies.

These findings represent a concern for post-menopausal women who are considering hormone therapy, said Dr. Chlebowski. They should take the results of this study into consideration and consult with their physicians before undergoing even short-term hormone therapy.

The study examined the use of conjugated equine estrogens plus medroxyprogesterone acetate for approximately five years. A total of 8,506 women were randomly assigned to receive a combination of estrogen (0.625 milligrams of conjugated equine estrogens per day) plus progesterone (2.5 milligrams of medroxyprogesterone acetate per day), while 8,102 took a placebo. Each woman received a mammogram and breast examination yearly, with biopsies performed based on physicians clinical judgment.

During the 5.6 years of the study, 199 women in the combined hormone group and 150 women in the placebo group developed breast cancer. Mammograms with abnormal results were more common among women taking hormones than among women taking placebos: 35 percent vs. 23 percent.

Women taking hormones had a 4 percent greater risk of having a mammogram with abnormalities after one year and an 11 percent greater risk after five years.

Breast biopsies also were more common among women taking combined hormone therapy than among those taking placebos: 10 percent vs. 6.1 percent.

After discontinuation of combined hormone therapy, the adverse effects on mammogram and breast biopsy performance were seen even in younger women in the fifth decade of life, so the finding may impact women just entering menopause as well, said Dr. Chlebowski.

The study found the adverse effect of combined hormone therapy on mammograms modulated but remained significantly different from that of placebo for at least 12 months, according to the studys authors.


'/>"/>

Contact: Laura Mecoy
Lmecoy@issuesmanagement.com
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. BioMed Realty Trust Joint Venture Enters Into New $245 Million Construction Loan and Extends Term of Existing Loan Facility
2. Dr. Inder Verma named recipient of 2008 Vilcek Prize in biomedical science
3. 7th Annual Wiley Prize in Biomedical Sciences Awarded to Dr. Richard P. Lifton
4. Lung Cancer Alliance Urges Inclusion of $5 Billion for Biomedical Research in Economic Stimulus Package
5. BioMed Central bolsters radiology image collection
6. New nanotube findings by Stanford researchers give boost to potential biomedical applications
7. American Red Cross Announces New Leader for Biomedical Services
8. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
9. BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends
10. LA BioMed researchers find few emergency rooms fully equipped for pediatric patients
11. LA BioMed research finds simpler way to assess breast cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 The vast ... an outpatient dialysis facility.  Treatments are usually 3 times ... hours per visit, including travel time, equipment preparation and ... patient, but especially grueling for patients who are elderly ... a skilled nursing and rehabilitation centers for some duration ...
(Date:6/23/2016)... Tenn. , June 23, 2016 /PRNewswire/ ... automating, integrating and transforming the patient payment ... of several innovative new products and services ... of its revenue cycle offerings. These award-winning ... more efficient workflows, remain compliant in an ...
(Date:6/23/2016)... -- The National Pharmaceutical Council (NPC) today announced that ... organization as its newest member.  ... and chief scientific officer, Mallinckrodt Pharmaceuticals, will serve ... of Directors. ... in support of our efforts to conduct research ...
Breaking Medicine Technology: